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ABSTRACT
Aim: This research was aimed to assess the potential for inhibition of protein binding of phenytoin
by tizoxanide in human plasma. Phenytoin was used because studies have proven to be a highly
plasma protein-bound drug with a narrow therapeutic index and non-linear pharmacokinetics.
Tizoxanide is another highly protein-bound active metabolite of an anti-infective prodrug
nitazoxanide. Both drugs are expected to be administered together due to their therapeutic
indications.
Study Design: The study was divided into two phases. Phase 1 produced a reference line of
phenytoin protein binding values. Phase 2 was conducted to reveal the effect of the interactant
tizoxanide on the protein binding of phenytoin. The results obtained from phase 1 were compared
with those of phase 2.
Methodology: Protein binding of phenytoin was studied using a centrifugal ultrafiltration method.
Protein binding of three phenytoin concentrations was studied: 25, 50, and 100 µg/mL. The
concentrations of phenytoin were analyzed by validated HPLC method. Each experiment was
performed in triplicate.
_____________________________________________________________________________________________________
*Corresponding author: E-mail: mariana.babayeva@touro.edu;
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Results: Co-administration of tizoxanide significantly inhibited protein binding of phenytoin for all
concentrations tested. Tizoxanide increased unbound fraction (fu) of phenytoin by 4.4, 3.7, and 2.8fold for concentration of 25, 50, and 100 µg/ml, respectively. Phenytoin was displaced from protein
binding sites what resulted in amplified unbound plasma levels of the antiepileptic drug.
Conclusion: Tizoxanide significantly inhibited protein binding of phenytoin in human plasma. The
interaction could potentially result in altered elimination and increased toxicity of phenytoin leading
to neuronal side effects and hypersensitivity reactions. Caution also should be taken when
administering nitazoxanide concurrently with other highly plasma protein-bound drugs, especially
drugs with narrow therapeutic indices, as competition for binding sites may occur.
Keywords: Protein binding; drug-drug interaction; phenytoin; tizoxanide.
distribution and clearance [3]. Outcome of the
protein binding interaction can be dangerous if
the displaced medication is highly bound to blood
proteins. Additional clinical risks include nonlinear
pharmacokinetics
and/or
narrow
therapeutic window of the affected drug. Such
drug-drug interaction may lead to exaggerated
therapeutic response as well as to acute and
chronic toxicity. For this reason, each drug
interaction is unique and should be analyzed on
a case-by-case basis. The simplified approach to
protein binding interactions is not ideal as each
active pharmaceutical ingredient possess
pharmacologically independent characteristics.
Measurement rather than estimation of free drug
levels should be used to achieve safety and
efficacy of highly protein bound medications.

1. INTRODUCTION
Patients treated with antiepileptic drugs
experience variability in therapeutic outcomes
including adverse effects. This is due to genetic
polymorphisms affecting metabolizing enzymes
and drug transporters, plasma/tissue protein
binding, and drug-drug interactions [1]. In
reference to genetic polymorphisms, ultra-rapid,
intermediate, and poor metabolizers demonstrate
differences in the CYP450 enzymatic process
and therefore, show variabilities in therapeutic
1
response and drug toxicity . Plasma protein
binding, another determinant of a drug’s
therapeutic effect, can affect pharmacokinetics
(PK) and pharmacodynamics (PD) of drugs [2].
Drugs in the body exist in two forms bound and
unbound (free). Bound drugs do not elicit a
therapeutic response because bound drugs are
not dynamically distributed to target organs and
don’t have affinity to target receptors. However,
free drugs reach their active sites, interact with
receptors and produce therapeutic effect.
Therefore, only unbound drugs are predictors of
a clinical efficacy or toxicity.

Phenytoin (PHT), 5,5-diphenylimidazolidine-2,4dione
(Dilantin™)
is
an
anticonvulsant
medication indicated for the management of
generalized tonic clonic seizures, complex partial
seizures, and for the prevention of seizures after
head trauma and neurosurgery [4]. Multiple
unlabeled indications of phenytoin include the
management of trigeminal neuralgia, syndrome
of inappropriate antidiuretic hormone (SIADH),
torsade de pointes, and arrhythmias [4]. The
drug is rapidly distributed to the brain where an
equilibrium in plasma and brain concentrations is
achieved. Phenytoin is metabolized by CYP2C9
and CYP2 C19 enzymes and is a broad-based
inducer of cytochrome P450 system. Phenytoin
is susceptible to metabolic drug interactions.
Cimetidine, valproic
acid, amiodarone,
chloramphenicol, isoniazid, disulfiram,
and omeprazole inhibit phenytoin metabolism
and increase phenytoin blood concentrations [5].
As inducer PHT increases metabolism of some
narrow therapeutic ranges drugs such as
phenobarbital,
cyclosporine, carbamazepine,
tacrolimus, and warfarin [5]. Moreover, phenytoin
is narrow therapeutic range drug with nonlinear,
Michaelis-Menten kinetics [4,6,7]. The clearance
and half-life of phenytoin are not constant and

Plasma proteins include albumins, ɑ, β, and ɣ
globulins, lipoproteins, and glycoproteins [3]. The
concentration of albumins is much greater than
concentrations of other proteins in human
plasma. Binding to blood proteins depends on
the physicochemical properties of drugs. Acidic
compounds are typically bound to albumins,
while basic medications connect to globulins.
Plasma protein binding interactions are
categorized
as
displacement
reactions.
Displacement interactions can be specific or nonspecific,
competitive
or
non-competitive.
Competitive displacements are leading drug-drug
reactions among all protein binding interactions.
The consequence of the drug-drug reaction is
increased free plasma concentrations of the
displaced medication. In turn, this impacts drug’s
pharmacokinetics
parameters:
volume
of
2
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depend on phenytoin plasma levels. Studies
discovered that phenytoin is approximately 90%
bound to plasma albumins while the unbound
form is responsible for pharmacologic activity
[7,8,9,10]. Since phenytoin is highly bound to
albumins, conditions that affect albumin levels
can also affect the unbound phenytoin
concentrations.
Disease-causing
hypoalbuminemia such as end-stage renal
disease (ESRD), burns, hepatic cirrhosis,
nephrotic syndrome, pregnancy, and cystic
fibrosis increase the fraction of unbound
phenytoin [6,11]. High free levels of PHT can
lead to exaggerated pharmacologic response
and toxicity. Endogenous (bilirubin) and/or
exogenous compounds might alter protein
binding of phenytoin as well. Drugs that are
highly bound to albumins and cause inhibition of
protein binding of PHT include warfarin, valproic
acid, and some highly bound nonsteroidal antiinflammatory
medications
[12,13,14].
Unbound phenytoin
plasma
concentrations
should be measured in patients with altered
phenytoin plasma protein binding [15]. When
unbound phenytoin
concentrations
are
unavailable, corrected phenytoin levels typically
are calculated.

The aim of this research was to identify the
possibility of displacement interaction between
phenytoin and tizoxanide.

2. MATERIALS AND METHODS
2.1 Materials
Phenytoin, DMSO, methanol, HPLC water,
potassium dihydrogen phosphate, and other
chemicals were obtained from Sigma-Aldrich (St
Louis, MO). Tizoxanide was purchased from
Cayman chemicals (Tallinn, Estonia). Human
plasma was obtained from Valley Biochemical,
Winchester, MA. HPLC filters (0.45 um, 47 mm)
were purchased from Pall Life Science (Port
Washington, NY). Amicon Centrifree YM-30
centrifugal filter units were obtained from
Millipore (Billerica, MA)

2.2 Study Groups
The study was divided into phases 1 and 2.
Phase 1 produced a reference line of phenytoin
protein binding values. Phase 2 was conducted
to reveal the effect of the interactant tizoxanide
on the protein binding of phenytoin. The
interactant was chosen based on the possibility
of a co-administration with phenytoin in clinical
practice and its protein binding characteristics.
The results obtained from phase 1 were
compared with those of phase 2. Each
experiment was performed in triplicate.

Nitazoxanide, also known by the brand
names Alinia® and Annita®, is a synthetic
nitrothiazolyl-salicylamide derivative belonging to
a class of thiazolides [16,17]. Nitazoxanide is
a broad-spectrum antiparasitic and antiviral drug
that
is
used
for
the
treatment
of
various helminthic, protozoal, and viral infections
[16,18,19,20,21]. Recently nitazoxanide was
purposed for the treatment of influenza [20,22]
and also was investigated as a potential therapy
for
chronic hepatitis
B
and
C, rotavirus
and norovirus gastroenteritis [20,23,24,25,26].

Analysis of variance (ANOVA) was applied to
assess differences in mean values of phenytoin
binding. This statistical method determined the
significant differences in protein binding between
the two study groups. Statistical significance was
detected at a p-value<0.05.

Nitazoxanide is a prodrug that rapidly hydrolyzed
to an active metabolite tizoxanide (TZX) [17,27].
The half-life of nitazoxanide in the plasma is very
short, approximately 6 minutes [28]. Tizoxanide
is highly bound to plasma proteins (>99%),
mostly to plasma albumin, as result of its acidic
property [29,30]. The half-life of TZX in plasma is
approximately 1.5 h [31,32].

2.3 HPLC Method for Phenytoin
The concentrations of phenytoin were analyzed
using validated High Liquid Performance
Chromatography (HPLC) technique. Peak
separation was achieved by C18 column (250 x
4.6 mm, 5 µm, 100 Å) through isocratic elution.
The stationary phase was temperature controlled
at 25°C. An ultraviolet detection wavelength of
250 nm was used to measure phenytoin peaks.
Mobile phase was prepared from 40% phosphate
buffer (pH 2.8) and 60% methanol. Other HPLC
variables include a constant flow rate of 0.7
mL/min, a run time of 10 minutes, and an

Nitazoxanide is a compound that is expected to
be co-administered with phenytoin clinically and
its active metabolite has the potential to alter
phenytoin protein binding. No drug-drug protein
binding interaction studies have been reported
for phenytoin and nitazoxanide and/or tizoxanide

3
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injection volume of 20 µL. Phenytoin retention
time was 7.9 minutes

The assessment of nonspecific binding to the
micropartition system yielded negligible binding
(fraction unbound ~ 1) to the units. Table 1
represents phenytoin protein binding results.

2.4 Protein Binding Determination

Phase 1 study formed a reference line of
phenytoin protein binding values. Mean free
fraction value of phenytoin was 0.14 in this
phase. This finding was consistent with
previously published data [8,9,10]. No significant
difference in protein binding was noted within the
study group.

A preliminary work was completed to assess
nonspecific binding of phenytoin to the
micropartition system (Amicon Centrifree YM-30
System). Three concentrations of phenytoin were
studied (25, 50 and 100 µg/mL). Ultrafiltration
units with aqueous solutions of phenytoin were
centrifuged at a relative force of 2000 g for 20
minutes. The ultrafiltrates were used to evaluate
nonspecific binding of the drug to the
micropartition devices. The concentrations of
phenytoin in filtrates were measured by HPLC.
Each experiment was done in triplicate.

Phase 2 was performed to evaluate effect of TZX
on protein binding of phenytoin. Mean free
fraction value of phenytoin was 0.48 with no
significant difference within this study group.
Tizoxanide significantly increased unbound
phenytoin concentrations by 4.4, 3.7, and 2.8fold for concentrations of 25 µg/mL, 50 µg/mL,
and 100 µg/mL, respectively

Following the assessment of nonspecific binding
was an analysis of phenytoin binding to plasma
proteins. The investigation was performed at
physiologic temperature (37°C) and pH. Human
plasma was spiked with stock solution of
phenytoin to produce samples of the following
concentrations: 25 µg/mL, 50 µg/mL, and 100
µg/mL. Tizoxanide was used only for phase 2
trials. Concentration of TZX was 500 µg/mL in
each sample. The resulting solutions were
incubated at 37°C for 30 minutes. One mL of
each sample was added to Amicon Centrifree
devices and centrifuged for 20 minutes at 2000
g. The ultrafiltrated samples were analyzed for
measuring free phenytoin concentrations by
previously mentioned HPLC method. All tests
were performed in triplicate.

4. DISCUSSION
This investigation was performed to evaluate the
potential effect of tizoxanide on protein binding of
phenytoin. Phenytoin was of particular interest
because of its high protein binding, narrow
therapeutic
window
and
non-linear
pharmacokinetics. Since phenytoin is a highly
protein bound drug, it was imperative to analyze
the effect of another extremely protein bound
drug on unbound concentrations of phenytoin.
Tizoxanide fits these criteria and is expected to
be co-administered with phenytoin in clinical
practice.

2.5 Data Analysis
The research revealed statistically significant
interaction between phenytoin and tizoxanide.
TZX significantly inhibited protein binding of PHT
in all concentrations tested. Phenytoin was
displaced from protein binding sites what
resulted in amplified unbound plasma levels of
the antiepileptic drug.

The fraction unbound (fu) of phenytoin was
calculated as a ratio of unbound (free)
concentration to total phenytoin concentration in
both phase 1 and 2 studies.

The both medications phenytoin and tizoxanide
are bound primarily to albumins and competed
for the same binding site of the proteins.
Albumins have two main drug binding sites,
Sudlow site I and Sudlow site II [33,34]. Drug
binding to these sites is selective. Tizoxanide
primarily binds to Sudlow site I [35]. Since
tizoxanide displaced phenytoin, it can be
assumed that PHT also binds to site I. The
bindings resulted in direct competition for the
shared Sudlow site I. This hypothesis requests
further examination.

Where: fu is unbound (free) fraction of phenytoin.
Cu is unbound (filtrate) concentration of
phenytoin.
Ct is total concentration of phenytoin.

3. RESULTS
Plasma protein binding of phenytoin was
evaluated by ultrafiltration technique. Protein
binding of three phenytoin concentrations was
studied: 25, 50, and 100 µg/mL.
4
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Table 1. Protein binding of phenytoin (PHT) in phase 1 and 2 studies
Study groups
Phase 1
PHT alone
Phase 2
PHT + TZX

PHT concentrations (µg/mL)
100
50
25
100
50
25

Fraction unbound of PHT*
0.17 (0.004)
0.13 (0.001)
0.11 (0.001)
0.47 (0.005)
0.48 (0.007)
0.48 (0.005)

*Data reported as mean (SD)

Non-linear pharmacokinetics makes phenytoin
dosing is extremely challenging. Moreover, other
drugs may modify the pharmacokinetics of
phenytoin by altering its plasma protein binding
and/or metabolism. It is commonly recognized
that only unbound phenytoin is pharmacologically
active. The development of side effects
correlates
better
with
free
phenytoin
concentrations than with total phenytoin
concentrations [36,37]. Metabolism of some
medications including PHT depends on unbound
fractions of the drugs. Protein binding inhibition
of drugs with linear PK lead to an increase in free
plasma levels, greater extent of metabolism,
increased
clearance,
and
lower
total
concentrations. Such interactions may result in
reduced effectiveness of the therapies. However,
non-linear PK makes the outcomes of phenytoin
protein binding interaction unpredictable. In case
of saturated metabolism, the total concentration
of phenytoin is often at the same level as before
the drug interaction occurred, but unbound
phenytoin concentrations are much higher. Such
interaction
may
result
in
phenytoin
poisonousness.
If
only
total
phenytoin
concentrations are measured, clinicians may be
under the impression that no drug interaction
happened. Unbound concentrations have to be
measured whenever possible with suspected
abnormal phenytoin plasma protein binding to
avoid phenytoin intoxication.

intoxication. Greater uptake of phenytoin into the
brain due to increased unbound level can lead to
serious neuronal side effects [39]. When highly
protein bound drugs are coadministered with
phenytoin, complete blood count, liver function,
cardiac function, respiratory function and
suicidality are among an extensive list of
monitoring parameters to be assessed [40].
The protein binding inhibition of phenytoin can
lead to changes in unbound concentrations and,
as a result, alteration in the clinical effect. To
avoid an unexpected change in pharmacologic
response, monitoring of unbound concentrations
is mandated and dose adjustments should be
implemented.

5. CONCLUSION
This investigation provided an important
understanding of protein binding displacement
interactions. Protein binding drug-drug interaction
was detected between phenytoin and tizoxanide.
TZX significantly inhibited protein binding of
phenytoin in human plasma. Therefore,
tizoxanide has the potential to modify protein
binding of PHT and rise free phenytoin
concentrations in patients. In addition, PHT is a
narrow therapeutic range drug and has nonlinear pharmacokinetics what make the drugdrug interaction even more complex. The
interaction could lead to great variations in
therapeutic response and result in amplified
toxicity of phenytoin treatment. For these
reasons, phenytoin dose adjustment may be
necessary
when
co-administered
with
nitazoxanide. Further studies are needed to
assess clinical significance of the finding as well
as find a strategy to improve clinical outcomes
and avoid toxicity of phenytoin therapy.

Previous studies have focused on the interaction
between valproic acid and phenytoin. Valproic
acid is a highly protein bound anticonvulsant.
Phenytoin
unbound
concentrations
were
increased by 50% via coadministration with
valproic acid [38]. This interaction has produced
serious side effects. Data from the present study
indicate that tizoxanide increased phenytoin
unbound concentration more than 50%. PHT as
a narrow therapeutic index drug poses major
changes in the pharmacological effect with only
small variations in unbound concentrations. Nonlinear PK makes the difference even more
dangerous and can produce phenytoin

Caution also should be taken when administering
nitazoxanide concurrently with other highly
plasma protein-bound drugs, especially drugs
with narrow therapeutic indices, as competition
for binding sites may occur. The pharmacokinetic
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alterations may result in complex changes in total
and unbound concentrations and drug response.
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